查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134971

全球多發性硬化症治療研發管線分析 - 2026 年（第二季洞察與臨床試驗）

Global Multiple Sclerosis Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

多發性硬化症 (MS) 的治療方案正在迅速發展，製藥和生物技術公司正在開發下一代療法，旨在減緩殘疾進展、保護神經功能、促進髓鞘再生，並改善復發型和進展型 MSC 的長期神經系統預後。

多發性硬化症 (MS) 是一種慢性中樞神經系統自體自體免疫疾病，其特徵是發炎性去髓鞘化、軸突變性和​​進行性神經功能障礙。雖然目前已獲批准的疾病修正治療能夠有效降低發炎性疾病活動度和復發率，但在治療進行性疾病、促進髓鞘修復和預防長期殘疾方面仍存在顯著的未滿足需求。藥物研發管線分析能夠全面深入了解在臨床實驗療法、臨床開發階段、作用機制、藥物製劑、申辦方活動、監管趨勢以及未來的商業化機會。

市場促進因素

擴大下一代疾病修正治療的研發

  • 對既能預防復發又能延緩殘疾進展的療法的需求日益成長，持續推動研發管線的擴張。製藥公司正大力投資於針對免疫調節、髓鞘再生、神經保護和再生醫學的創新療法。

加大對精準免疫學的投資

  • 免疫學和分子神經科學的進步正在加速開發能夠選擇性調節免疫反應並最大限度減少全身性免疫抑制的療法。布魯頓蛋白酪氨酸激酶（BTK）抑制劑、抗原特異性免疫耐受療法和基於生物標記的治療策略正成為研發管線重點投資領域。

人們越來越關注進行進行性多發性硬化症

  • 鑑於人們越來越意識到次發漸進型和首發漸進型多發性硬化症的治療選擇有限，藥物研發人員正在優先開發能夠減緩疾病進展和保護神經功能的療法。

藥物發現技術的進步

  • 人工智慧、電腦輔助藥物發現、基因組醫學、先進的影像生物標記和數位臨床試驗技術正在提高標靶識別、患者選擇和臨床開發的效率，從而加速研發管線的進展。

市場限制因素

複雜疾病的生物學特徵

  • 多發性硬化症的病理類型多樣，包括復發緩解型、次發漸進型和首發漸進型，這給尋找療效廣泛的治療方法和設計成功的臨床試驗帶來了重大挑戰。

長期臨床開發

  • 多發性硬化症藥物的研發需要對復發抑制、殘疾進展、MRI觀察和安全性進行廣泛而長期的評估，這導致了較長的研發週期和大量的研究投入。

嚴格的監管要求

  • 監管機構要求提供全面的證據，證明藥物具有持續療效、長期安全性、患者報告結果以及顯著降低殘疾進展，這增加了藥物研發的複雜性。

管道和技術方面的見解

  • 全球多發性硬化症治療藥物研發管線可依臨床開發階段、作用機轉、藥物類型、目標患者群及地區分類。
  • 從臨床開發階段來看，產品線涵蓋臨床前、I期、II期、III期臨床試驗以及已提交核准或正在接受監管審查的藥物。中期開發依然活躍，但後期開發案正日益關注針對進行性疾病和長期殘疾的療法。
  • 從作用機制來看，此研發管線涵蓋免疫調節劑、B細胞標靶治療、T細胞調節劑、BTK抑制劑、髓鞘再生療法、神經保護療法、抗原特異性免疫耐受療法、幹細胞療法以及其他新興作用機制。目前，BTK抑制劑和髓鞘再生療法是研發中最具競爭力和發展最快的兩個領域。
  • 從藥物類型來看，目前處於臨床實驗的產品包括小分子化合物、生物製藥、細胞療法、基因療法、RNA療法和聯合治療。雖然小分子化合物仍佔據研發管線的主導地位，但隨著科學知識的進步，再生醫學和基因療法正在迅速發展。
  • 從目標患者群體來看，復發型多發性硬化症(RRMS)、次發漸進型多發性硬化症 (SPMS)、首發漸進型多發性硬化症 (PPMS)、臨床孤立症候群 (CIS) 以及更廣泛的多發性硬化症患者的療法。尤其值得關注的是，針對進行性疾病的療法正日益受到重視，因為這類疾病仍有顯著的未滿足醫療需求。
  • 人工智慧、數位生物標記、先進的 MRI 成像、神經絲輕鏈生物標記、分散式臨床試驗、穿戴式監測設備和真實世界證據平台等技術進步不斷提高藥物發現和臨床決策的效率。

管道開發趨勢

  • 多發性硬化症的治療方案正在不斷多樣化，從傳統的抗發炎療法轉向能夠延緩疾病進展的療法。

主要管道發展趨勢如下：

  • BTK抑制劑研發計畫迅速擴展。
  • 增加對髓鞘再生和再生醫學的投入。
  • 人們越來越關注神經保護治療。
  • 基於生物標記的精準醫療的拓展。
  • 人工智慧（AI）在藥物研發中的應用日益廣泛。
  • 生物技術公司與跨國製藥公司之間的策略夥伴關係。
  • 人們越來越重視的不僅是預防復發，還有針對進行進行性多發性硬化症的治療。

區域趨勢

  • 由於北美擁有先進的神經科學研究基礎設施、製藥業的巨額投資、積極的臨床試驗活動以及大量的確診患者，因此北美仍然是多發性硬化症治療發展的領先地區。
  • 歐洲透過與學術研究機構、已建立的神經系統治療中心以及協調一致的監管指導開展合作，繼續發揮至關重要的作用，從而支持跨國臨床開發。
  • 預計在預測期內，亞太地區將經歷最快的成長，這主要得益於生物技術能力的提升、治療神經系統疾病的基礎設施的改善、研究投資的增加以及中國、日本、韓國、印度和澳洲等國參與多國臨床試驗的人數不斷增加。
  • 在拉丁美洲、中東和非洲，透過醫療保健現代化、診斷服務改進以及更多參與國際發展項目，臨床研究能力正在逐步加強。

競爭格局

  • 多發性硬化症治療藥物研發管線涵蓋跨國製藥公司、生物技術公司、學術研究機構、合約研究組織 (CRO) 和專注於神經科學的創新公司。
  • 各公司持續投資於差異化免疫療法、再生醫學、基於生物標記的研發、人工智慧驅動的藥物發現以及精準醫療技術。策略授權協議、併購、聯合開發夥伴關係和研究合作對於加強開發平臺和加速商業化仍然至關重要。
  • 競爭越來越集中在能夠減緩疾病進展、促進髓鞘再生、維持神經細胞健康以及改善長期功能結果的療法。

未來展望

  • 多發性硬化症藥物研發的未來預計將受到神經免疫學、再生醫學、精準免疫學、生物標記科學、人工智慧和個人化神經病學等領域進展的影響。未來的創新將越來越專注於不僅抑制炎症，而且能夠改變疾病進展、修復髓鞘損傷並預防不可逆神經損傷的療法。
  • 數位生物標記、適應性臨床試驗設計、真實世界數據和精準醫療技術的整合可望提高研發成功率，同時加快法規核准和商業化進程。

結論

全球多發性硬化症治療管線分析市場預計將持續成長至2035年，其主要驅動力包括神經科學研究投入的增加、新一代疾病修正治療的快速發展、再生醫學的進步以及精準免疫學的廣泛應用。儘管疾病異質性、漫長的臨床開發週期和複雜的監管環境等挑戰依然存在，但BTK抑制劑、髓鞘再生療法、神經保護劑、基於生物標記的療法以及人工智慧等領域的持續創新有望改變未來的治療格局，為製藥公司、生物技術公司、投資者和醫療保健機構創造巨大的機會。

本報告的主要益處

  • 對全球多發性硬化症治療藥物研發管線及未來發展趨勢進行全面分析。
  • 在臨床實驗期間，對治療方法、作用機制和臨床開發階段進行詳細評估。
  • 對主要開發公司、管道資產和策略聯盟進行競爭分析。
  • 深入了解監管趨勢、商業化機會和創新策略。
  • 這將成為製藥公司、生技公司、研究人員、投資者、醫療保健專業人員、顧問和政策制定者的重要資訊來源。

公司對我們報告的使用

  • 產品線基準分析、競爭情報分析、產品組合最佳化、許可和合作評估、投資分析、臨床開發規劃、商業化策略、監管合規規劃以及新治療機會的識別。

調查範圍

  • 歷史資料涵蓋 2021 年至 2025 年，基準年為 2025 年，預測期間為 2026 年至 2035 年。
  • 對多發性硬化症治療產品線進行全面分析，分析維度包括臨床開發階段、作用機制、藥物類型、目標患者群體和地區。
  • 臨床實驗治療方案評估、研發管線成熟度、申辦者活動、監管趨勢與創新趨勢。
  • 授權協議、策略聯盟、併購和競爭定位評估。
  • 分析新興技術、精準免疫學、再生醫學、生物標記整合以及 2035 年的未來商業化機會。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：多發性硬化症研發管線的發展趨勢

  • 促進因素
  • 抑制因子
  • 潛在機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Novartis
    • Sanofi
    • F. Hoffmann-La Roche
    • Merck KGaA
    • Biogen
  • 管線分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • 復發型多發性硬化症
    • 次發漸進型性多發性硬化症
    • 原發性進行性多發性硬化症
    • 臨床孤立症候群
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 進行中，參與者招募已結束。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 贊助商和合作研究者分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Novartis
  • Sanofi
  • F. Hoffmann-La Roche
  • Merck KGaA
  • Biogen

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008943

The Multiple Sclerosis drug pipeline is rapidly evolving as pharmaceutical and biotechnology companies develop next-generation therapies designed to reduce disability progression, preserve neuronal function, promote remyelination, and improve long-term neurological outcomes across both relapsing and progressive forms of multiple sclerosis.

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by inflammatory demyelination, axonal degeneration, and progressive neurological disability. Although currently approved disease-modifying therapies effectively reduce inflammatory disease activity and relapse rates, significant unmet needs remain in treating progressive disease, promoting myelin repair, and preventing long-term disability. Drug pipeline analysis provides comprehensive insights into investigational therapies, clinical development phases, mechanisms of action, drug modalities, sponsor activities, regulatory developments, and future commercialization opportunities.

Market Drivers

Expanding Development of Next-Generation Disease-Modifying Therapies

  • The increasing demand for therapies capable of slowing disability progression beyond relapse control continues to drive pipeline expansion. Pharmaceutical companies are investing heavily in innovative treatments targeting immune modulation, remyelination, neuroprotection, and regenerative medicine.

Growing Investment in Precision Immunology

  • Advances in immunology and molecular neuroscience have accelerated the development of therapies that selectively regulate immune responses while minimizing systemic immunosuppression. Bruton tyrosine kinase (BTK) inhibitors, antigen-specific immune tolerance therapies, and biomarker-guided treatment strategies are becoming major areas of pipeline investment.

Increasing Focus on Progressive Multiple Sclerosis

  • Growing recognition of the limited treatment options available for secondary progressive and primary progressive multiple sclerosis has encouraged developers to prioritize therapies capable of reducing disability progression and preserving neurological function.

Advances in Drug Discovery Technologies

  • Artificial intelligence, computational drug discovery, genomic medicine, advanced imaging biomarkers, and digital clinical trial technologies are improving target identification, patient selection, and clinical development efficiency, accelerating pipeline advancement.

Market Restraints

Complex Disease Biology

  • The heterogeneous nature of multiple sclerosis, including relapsing-remitting, secondary progressive, and primary progressive disease forms, creates significant challenges in identifying broadly effective therapies and designing successful clinical trials.

Lengthy Clinical Development

  • Drug development for multiple sclerosis requires extensive long-term evaluation of relapse reduction, disability progression, MRI outcomes, and safety, resulting in prolonged development timelines and substantial research investment.

Stringent Regulatory Requirements

  • Regulatory agencies require comprehensive evidence demonstrating durable efficacy, long-term safety, patient-reported outcomes, and meaningful reductions in disability progression, increasing development complexity.

Pipeline and Technology Insights

  • The global multiple sclerosis drug pipeline can be segmented by clinical development phase, mechanism of action, drug modality, target patient population, and geography.
  • By clinical development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and filed or under regulatory review assets. Mid-stage development remains highly active, while late-stage programs increasingly focus on therapies addressing progressive disease and long-term disability.
  • By mechanism of action, the pipeline includes immunomodulators, B-cell targeted therapies, T-cell modulators, BTK inhibitors, remyelination therapies, neuroprotective therapies, antigen-specific immune tolerance therapies, stem cell-based therapies, and other emerging mechanisms. BTK inhibitors and remyelination therapies currently represent two of the most competitive and rapidly expanding areas of development.
  • By drug modality, investigational products include small molecules, biologics, cell therapies, gene therapies, RNA therapeutics, and combination therapies. Small molecules continue to dominate pipeline activity, while regenerative medicine and gene-based approaches are expanding rapidly as scientific understanding improves.
  • By target patient population, therapies are being developed for relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS), clinically isolated syndrome (CIS), and broader multiple sclerosis populations. Increasing emphasis is being placed on therapies capable of addressing progressive disease, where significant unmet clinical needs remain.
  • Technological advances including artificial intelligence, digital biomarkers, advanced MRI imaging, neurofilament light chain biomarkers, decentralized clinical trials, wearable monitoring devices, and real-world evidence platforms continue to improve drug development efficiency and clinical decision-making.

Pipeline Development Trends

  • The multiple sclerosis pipeline continues to diversify beyond conventional anti-inflammatory approaches toward therapies capable of modifying disease progression.

Major pipeline trends include:

  • Rapid expansion of BTK inhibitor development programs.
  • Increasing investment in remyelination and regenerative therapies.
  • Growing focus on neuroprotective treatment strategies.
  • Expansion of biomarker-guided precision medicine.
  • Increased adoption of artificial intelligence in drug discovery.
  • Strategic collaborations between biotechnology companies and multinational pharmaceutical organizations.
  • Greater emphasis on therapies targeting progressive multiple sclerosis rather than relapse control alone.

Regional Insights

  • North America remains the leading region for multiple sclerosis drug development due to advanced neuroscience research infrastructure, strong pharmaceutical investment, extensive clinical trial activity, and a large diagnosed patient population.
  • Europe continues to play a major role through collaborative academic research, established neurological treatment centers, and harmonized regulatory guidance supporting multinational clinical development.
  • Asia-Pacific is expected to experience the fastest growth during the forecast period owing to expanding biotechnology capabilities, improving neurological care infrastructure, increasing investment in research, and growing participation in multinational clinical trials across China, Japan, South Korea, India, and Australia.
  • Latin America and the Middle East & Africa are gradually strengthening clinical research capabilities through healthcare modernization, improved diagnostic services, and increased participation in international development programs.

Competitive Landscape

  • The multiple sclerosis drug pipeline includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations, and neuroscience-focused innovators.
  • Companies continue to invest in differentiated immunotherapies, regenerative medicine, biomarker-guided development, artificial intelligence-assisted drug discovery, and precision medicine technologies. Strategic licensing agreements, mergers and acquisitions, co-development partnerships, and research collaborations remain essential for strengthening development pipelines and accelerating commercialization.
  • Competition increasingly focuses on therapies capable of slowing disability progression, promoting remyelination, preserving neuronal integrity, and improving long-term functional outcomes.

Future Outlook

  • The future of the multiple sclerosis drug pipeline is expected to be shaped by advances in neuroimmunology, regenerative medicine, precision immunology, biomarker science, artificial intelligence, and personalized neurology. Future innovation will increasingly emphasize therapies capable of modifying disease progression, repairing myelin damage, and preventing irreversible neurological disability rather than controlling inflammation alone.
  • Growing integration of digital biomarkers, adaptive clinical trial designs, real-world evidence, and precision medicine technologies is expected to improve development success rates while accelerating regulatory approvals and commercialization.

Conclusion

The global Multiple Sclerosis Drug Pipeline Analysis market is expected to experience sustained growth through 2035, supported by expanding investment in neuroscience research, increasing development of next-generation disease-modifying therapies, advances in regenerative medicine, and growing adoption of precision immunology. Although challenges including disease heterogeneity, lengthy clinical development, and regulatory complexity remain, ongoing innovation in BTK inhibitors, remyelination therapies, neuroprotective agents, biomarker-guided treatment, and artificial intelligence is expected to transform the future therapeutic landscape and create significant opportunities for pharmaceutical companies, biotechnology firms, investors, and healthcare providers.

Key Benefits of this Report

  • Comprehensive analysis of the global multiple sclerosis drug pipeline and future development trends.
  • Detailed evaluation of investigational therapies, mechanisms of action, and clinical development phases.
  • Competitive assessment of leading developers, pipeline assets, and strategic collaborations.
  • Insights into regulatory developments, commercialization opportunities, and innovation strategies.
  • Valuable resource for pharmaceutical companies, biotechnology firms, researchers, investors, healthcare providers, consultants, and policymakers.

What Businesses Use Our Reports For

  • Pipeline benchmarking, competitive intelligence, portfolio optimization, licensing and partnership evaluation, investment analysis, clinical development planning, commercialization strategy, regulatory planning, and identification of emerging therapeutic opportunities.

Report Coverage

  • Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the multiple sclerosis drug pipeline by clinical development phase, mechanism of action, drug modality, target patient population, and geography
  • Evaluation of investigational therapies, pipeline maturity, sponsor activities, regulatory developments, and innovation trends
  • Assessment of licensing agreements, strategic collaborations, mergers and acquisitions, and competitive positioning
  • Analysis of emerging technologies, precision immunology, regenerative medicine, biomarker integration, and future commercialization opportunities through 2035.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. MULTIPLE SCLEROSIS PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Novartis
    • 5.1.2. Sanofi
    • 5.1.3. F. Hoffmann-La Roche
    • 5.1.4. Merck KGaA
    • 5.1.5. Biogen
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. Relapsing-Remitting MS
    • 5.4.2. Secondary Progressive MS
    • 5.4.3. Primary Progressive MS
    • 5.4.4. Clinically Isolated Syndrome
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Novartis
  • 6.2. Sanofi
  • 6.3. F. Hoffmann-La Roche
  • 6.4. Merck KGaA
  • 6.5. Biogen

7. LIST OF TABLES

8. LIST OF FIGURES